
Acura Pharmaceuticals Inc Profile last edited on: 6/6/2024
CAGE: 6ZMA1
UEI: QBFKBYCMM2Z2
Business Identifier: Abuse-resistant products for pain and nasal congestion Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
616 N North Court Suite 120
Palatine, IL 60067
Palatine, IL 60067
(847) 705-7709 |
info@acurapharm.com |
www.acurapharm.com |
Location: Multiple
Congr. District: 05
County: Cook
Congr. District: 05
County: Cook
Public Profile
Acura Pharmaceuticals, Inc is a specialty pharmaceutical companyy involved in development of products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : ACURIP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2014 | 1 | NIH | $299,694 | |
Project Title: A Proposal To Develop A Self-Regulating Hydromorphone Tablet To Deter Excess Oral |
Key People / Management
Robert B Jones -- Chief Exec. Officer, Pres and Director
Albert W Brzeczko -- VP of Technical Affairs
Peter A Clemens -- Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
James Emigh -- Vp, Corporate Development
J Bradley Rivet -- VP of Marketing
Robert A Seiser -- VP, Treasurer and Corp. Controller
Albert W Brzeczko -- VP of Technical Affairs
Peter A Clemens -- Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
James Emigh -- Vp, Corporate Development
J Bradley Rivet -- VP of Marketing
Robert A Seiser -- VP, Treasurer and Corp. Controller
Company News
There are no news available.